What Is Cagrilintide? A Guide to the the Amylin Analog

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

---

Amylin research has historically centered on pramlintide, the first synthetic amylin analog to reach clinical evaluation. Cagrilintide represents a structurally distinct approach — a lipidated, long-acting analog engineered to address pramlintide’s serum stability limitations and expand the receptor-targeting profile available to researchers.

This article walks through cagrilintide’s molecular design, its binding profile across amylin and calcitonin receptor subtypes, and what preclinical and study-model data reveal about its pharmacological activity. All content is framed for laboratory and preclinical research contexts.

---

What Is Amylin and Why It Matters in Metabolic Research

Amylin is a neuroendocrine polypeptide hormone co-secreted with insulin by pancreatic beta cells in response to nutrient intake.

Its primary relevance to metabolic research lies in its satiety signaling role. Amylin targets multiple regions of the central nervous system, with the area postrema (AP) — a circumventricular organ in the caudal hindbrain — identified as its primary site of action in preclinical models.

From the AP, signal propagation extends through the nucleus of the solitary tract (NTS) and the lateral parabrachial nucleus (LPBN), circuits associated with appetite regulation and energy balance in rodent research.

Amylin also acts on agouti-related peptide (AgRP) and pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus, where it may contribute to energy expenditure modulation independent of the AP pathway.

Native amylin is prone to fibril formation and carries a short serum stability period — pharmacokinetic limitations that drove the development of engineered analogs including pramlintide and, more recently, cagrilintide.

Related Product: Buy Cagrilintide for in vitro laboratory research applications.

What is Cagrilintide?

Cagrilintide (also designated AM833) was developed using structure-activity relationship modeling, with the objective of producing a long-acting amylin analog with retained AMY3R affinity and reduced fibrillation risk.

Several targeted modifications distinguish it from native amylin and pramlintide.

• Lipidation: A C20 fatty acid chain attached at the N-terminus supports reversible albumin binding — a well-documented mechanism for extending the serum stability period of peptide hormones. Cagrilintide’s serum stability period has been measured at approximately 159–195 hours in study models, supporting once-weekly compound application intervals.
• Proline substitutions (25P/28P/29P): Analogous to rat amylin, these substitutions reduce beta-sheet propensity and inhibit fibril formation, a defining limitation of native amylin.
• Salt bridge mutations (14E/17R): These mutations are expected to stabilize the central helix of the peptide through intramolecular salt bridge formation.
• C-terminal proline: Added to selectively increase potency at the calcitonin receptor (CTR), completing cagrilintide’s non-selective DACRA receptor profile.

For researchers working in peptide modification and lipidation, the structural vocabulary underlying these modifications is outlined in our peptide glossary.

Receptor Binding Profile: AMY1R, AMY3R, and CTR

Amylin binds to heteromeric receptor complexes formed by the calcitonin receptor (CTR) combined with receptor activity-modifying proteins 1, 2, or 3 (RAMP1–3), generating three distinct amylin receptor subtypes: AMY1R, AMY2R, and AMY3R.

CTR alone carries higher affinity for calcitonin. Combined with RAMP subunits, it gains substantially greater affinity for amylin.

Cagrilintide is classified as a non-selective agonist across AMYRs and CTR — a DACRA. Receptor pharmacology research published in the Journal of Pharmacology and Experimental Therapeutics characterized cagrilintide’s pharmacological profile across 25 endpoints in cell lines expressing primate, rat, and mouse receptor variants, including HEK293 cells transfected with CTR and AMY3R constructs. Cagrilintide activated AMY1R and CTR with roughly equivalent potency across species in cAMP assays.

This non-selective binding pattern distinguishes it from AMY1R-selective analogs in development and from pramlintide’s more restricted receptor profile.

How Cagrilintide Differs From Salmon Calcitonin in In Vitro Models

Salmon calcitonin (sCT) is the most commonly used reference compound for DACRA research, sharing cagrilintide’s receptor targets.

The key pharmacodynamic distinction lies in receptor residence time. In vitro receptor data show cagrilintide dissociates from all receptor subtypes within 3–6 minutes, while sCT residence times range from 45–60 minutes across the same receptors.

This kinetic difference produces distinct downstream cAMP signaling profiles. Cagrilintide’s cAMP activation in cell assays returns to baseline within a few hours post-application, while sCT maintains a sustained cAMP response. The contrasting body weight outcomes observed between these two compounds in rodent models have been attributed in part to these receptor dynamics.

Preclinical Receptor Research: What In Vivo Models Reveal

A 2025 study published in eBioMedicine by Carvas et al. (University of Zurich, in consortium with the Novo Nordisk Foundation) provides the most detailed in vivo mechanistic data currently available for cagrilintide’s receptor specificity.

Using RAMP1/3 double-knockout (KO) mice on a high-fat diet, the study compared subchronic treatment outcomes in wild-type and KO animals over a 21-day protocol.

Key observations from the study:

• Cagrilintide produced a sustained body mass reduction in wild-type mice (−3.4 g by day 21, P < 0.005) with no body mass effect in RAMP1/3 KO animals
• The body mass reduction in wild-type mice was accompanied by a reduction in relative fat mass and maintenance of relative lean mass — a pattern absent in KO animals
• Plasma leptin levels decreased approximately 2-fold in wild-type cagrilintide-treated mice versus vehicle-treated controls

These results confirm that cagrilintide’s effects in these preclinical models are mediated through AMY1R and AMY3R rather than through independent CTR activation.

Area Postrema Neuronal Activation in Preclinical Models

The same study assessed neuronal activity using cFos immunostaining across the AP, NTS, and LPBN following acute compound application.

In wild-type mice, cagrilintide produced measurable cFos signal in AP, NTS, and LPBN neurons. In RAMP1/3 KO mice, AP cFos signal following cagrilintide application was reduced by 57% versus wild-type animals (P < 0.001).

A second cohort using RAMP1 KO, RAMP3 KO, and RAMP1/3 KO mice confirmed that cagrilintide-induced cFos activation in the AP was reduced across all single and double KO genotypes, pointing to both AMY1R and AMY3R as necessary components of the full neuronal activation response.

This receptor-specific mechanistic framework is directly relevant to laboratory research into amylin receptor pharmacology, GPCR signaling, and body composition modeling. For related in vitro contexts using metabolic peptides, our research overviews on AOD9604 and Tesamorelin cover adjacent preclinical research profiles.

Study Observations: Trial Data From Human Study Models

Cagrilintide is currently the subject of multiple Phase 2 and Phase 3 trials. The following summarizes study findings reported in peer-reviewed and congress-presented data, framed as observations from controlled study models.

Phase 2 — CagriSema in Type 2 Diabetes Study Populations (Lancet, 2023)

Frias et al. reported findings from a 32-week Phase 2 multicentre study in which participants received once-weekly co-administration of cagrilintide 2.4 mg and semaglutide 2.4 mg (CagriSema), cagrilintide alone, or semaglutide alone. Mean body weight change from baseline in the CagriSema group was −15.6%, versus −8.1% for cagrilintide monotherapy and −5.1% for semaglutide — an observation consistent with additive activity across two distinct receptor pathways.

Phase 3 — REDEFINE 2 (New England Journal of Medicine, 2025)

The REDEFINE 2 trial, published in the New England Journal of Medicine, evaluated CagriSema versus placebo in adults with overweight or obesity and type 2 diabetes across 12 countries. Estimated mean body weight change at 68 weeks was −13.7% in the CagriSema group versus −3.4% with placebo (estimated difference −10.4 percentage points, 95% CI −11.2 to −9.5, P < 0.001).

Phase 3 — REDEFINE 1 Monotherapy Sub-Analysis (EASD Congress, 2025)

A sub-analysis from the REDEFINE 1 trial — representing the first Phase 3 data for a long-acting amylin analog as monotherapy — reported an average body weight reduction of 11.8% with cagrilintide 2.4 mg versus 2.3% with placebo at 68 weeks, in a population of adults with obesity or overweight without type 2 diabetes. Additionally, 31.6% of participants in the cagrilintide group reached more than 15% body weight reduction versus 4.7% with placebo.

For broader context on where amylin analog research sits within the current metabolic peptide field, see BLL’s 2026 Peptide Industry Report.

Potential In Vitro Research Applications

Research Area	Potential In Vitro Application
Amylin receptor pharmacology	AMY1R/AMY3R binding selectivity and kinetics in transfected cell line assays
GPCR signaling characterization	cAMP pathway assays and G-protein recruitment profiling at CTR/AMYR heterodimers
Lipidated peptide stability	Albumin binding dynamics and serum stability period studies in plasma models
Appetite pathway modeling	Hindbrain neuropeptide circuit modeling using DACRA receptor agonist data
Combinatorial receptor research	Parallel receptor targeting studies alongside GLP-1R agonists in multi-receptor assay formats
Body composition modeling	Fat mass versus lean mass partitioning studies using RAMP subunit-specific preclinical approaches

All BioLongevity Labs compounds are supplied for in vitro laboratory research only.

Cagrilintide in the Research Landscape

Cagrilintide occupies a well-defined position among amylin-class compounds.

Its extended serum stability period, non-selective DACRA receptor profile, and precisely characterized molecular modifications make it one of the most thoroughly studied amylin analogs currently in active Phase 3 evaluation.

For laboratories researching GPCR pharmacology, amylin pathway signaling, or lipidated peptide behavior in preclinical models, cagrilintide’s expanding body of in vitro and in vivo data offers a well-sourced mechanistic reference.

BioLongevity Labs supplies research-grade peptides and bioregulators with triple third-party testing and full COA documentation for every batch. Browse the full peptide catalog or review available Certificates of Analysis at biolongevitylabs.com/all-coas/.

References

1. Fletcher, M. M., Keov, P., Truong, T. T., Mennen, G., Hick, C. A., Zhao, P., Furness, S. G. B., Kruse, T., Clausen, T. R., Wootten, D., & Sexton, P. M. (2021). AM833 is a novel agonist of calcitonin family G protein-coupled receptors: Pharmacological comparison with six selective and nonselective agonists. Journal of Pharmacology and Experimental Therapeutics, 377(3), 417–440. https://doi.org/10.1124/jpet.121.000567
2. Carvas, A. O., Leuthardt, A., Kulka, P., Lommi, G., Hassan, S., Coester, B., Lundh, S., Pers, T., Secher, A., Raun, K., Lutz, T. A., & Le Foll, C. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine, 118, 105836. https://doi.org/10.1016/j.ebiom.2025.105836
3. Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: A multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet, 402(10403), 720–730. https://doi.org/10.1016/S0140-6736(23)01163-7
4. REDEFINE 2 Study Group. (2025). Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes. New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMoa2502082
5. Novo Nordisk. (2025, September). Cagrilintide 2.4 mg monotherapy: Sub-analysis of the phase 3 REDEFINE 1 trial (NCT05567796) [Conference presentation]. European Association for the Study of Diabetes Annual Congress, Vienna, Austria.